Author

S. Holdenrieder

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

C. Hagen· 1 shared E. Bartok· 1 shared G. Hartmann· 1 shared J. G. van den Boorn· 1 shared M. Renn· 1 shared M. Schlee· 1 shared P. Müller· 1 shared S. Garbe· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

C. Hagen

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanoma

S. Lambing, S. Holdenrieder, P. Müller, Y. P. Tan, C. Hagen, S. Garbe, M. Schlee, J. G. van den Boorn, E. Bartok, G. Hartmann, M. Renn

This study shows that RIG-I ligands enhance radiation-induced tumor cell death and immunogenicity in melanoma, with p53 playing a key role in the synergy between RIG-I and radiation.

bioRxiv · Oct 16, 2021Immunology